Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study

被引：0

作者：

Coleman, Robert ^{[1
]}

Oaknin, Ana ^{[2
]}

Pignata, Sandro ^{[3
]}

Denys, Hannelore ^{[4
]}

Colombo, Nicoletta ^{[5
]}

Van Gorp, Toon ^{[6
]}

Konner, Jason ^{[7
]}

Marin, Margarita Romeo ^{[8
]}

Harter, Philipp ^{[9
]}

Murphy, Conleth ^{[10
]}

Esteves, Brooke ^{[11
]}

Method, Michael ^{[11
]}

Lorusso, Domenica ^{[12
]}

Matulonis, Ursula ^{[13
]}

机构：

[1] US Oncol Res, The Woodlands, TX USA

[2] Vall Hebron Inst Oncol, Barcelona, Spain

[3] Ist Nazl Tumori Napoli Fdn G Pascale, Naples, Italy

[4] Ghent Univ Hosp, Ghent, Belgium

[5] European Inst Oncol IRCCS, Milan, Italy

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Mem Sloan Kettering Canc Ctr, New York, NY USA

[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[9] Kliniken Essen Mitte, Essen, Germany

[10] Bon Secours Hosp Cork & Canc Trials, Cork, Ireland

[11] ImmunoGen Inc, Waltham, MA USA

[12] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

[13] Dana Farber Canc Inst, Boston, MA USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 176卷

关键词：

D O I：

10.1016/j.ygyno.2023.06.468

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

002

引用

页码：S3 / S3

页数：1

共 50 条

[1] Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
Matulonis, Ursula A.
Oaknin, Ana
Pignata, Sandro
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason A.
Romeo, Marga
Harter, Philipp
Murphy, Conleth G.
Wang, Jiuzhou
Method, Michael W.
Esteves, Brooke
Coleman, Robert L.
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Matulonis, Ursula A.
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Dean, Andrew
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason A.
Marin, Margarita Romeo
Harter, Philipp
Murphy, Conleth G.
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert L.
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (06) : 343 - 344
[3] Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Matulonis, Ursula A. A.
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Dean, Andrew
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason A. A.
Marin, Margarita Romeo
Harter, Philipp
Murphy, Conleth G. G.
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert L. L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2436 - +
[4] Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Matulonis, Ursula
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason
Romeo Marin, Margarita
Harter, Philipp
Murphy, Conleth
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
Coleman, Robert
GYNECOLOGIC ONCOLOGY, 2022, 166 : S50 - S50
[5] Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
Coleman, Robert L.
Lorusso, Domenica
Oaknin, Ana
Cecere, Sabrina Chiara
Denys, Hannelore
Colombo, Nicoletta
van Gorp, Toon
Konner, Jason A.
Marin, Margarita Romeo
Harter, Philipp
Murphy, Conleth
Wang, Yuemei
Esteves, Brooke
Method, Michael
Matulonis, Ursula
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (08) : 1119 - 1125
[6] Efficacy and safety of mirvetuximab soravtansine in Chinese patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from IMGN853-301 (Soraya China) study
Li, Li
Wu, Yong
Li, Qingshui
Yu, Aijun
Lin, An
Li, Guiling
Zhang, Huifeng
Wang, Jing
Li, Li
Yin, Rutie
Wei, Bing
Li, Jundong
Chen, Lihong
Zhao, Weidong
Wang, Wuliang
Zhang, Qinghua
Xu, June
Wu, Xiaohua
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A210 - A210
[7] CLINICAL BENEFIT OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER PATIENTS WITH HIGH FOLATE RECEPTOR ALPHA EXPRESSION: RESULTS FROM THE SORAYA STUDY
Coleman, Robert L.
Matulonis, Ursula
Lorusso, Domenica
Oaknin, Ana
Pignata, Sandro
Denys, Hannelore
Colombo, Nicoletta
Van Gorp, Toon
Konner, Jason
Romeo Marin, Margarita
Harter, Philipp
Murphy, Conleth
Wang, Jiuzhou
Noble, Elizabeth
Esteves, Brooke
Method, Michael
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A18 - A18
[8] Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis
Zhu, Youwen
Lin, Yinxin
Liu, Kun
Zhu, Hong
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (06)
[9] Mirvetuximab soravtansine (MIRV) in recurrent platinum-sensitive ovarian cancer (PSOC) with high folate receptor-alpha (FRα) expression: Results from the PICCOLO trial
Secord, A. A.
Corr, B. R.
Lewin, S.
Diver, E.
Ayuk, S-M.
Wang, Y.
Murphy, C.
Salutari, V.
Garcia, A. Barquin
Montosa, F. Galvez
Ray-Coquard, I. L.
Mathews, C.
Konecny, G. E.
Oaknin, A.
Perez, M. J. Rubio
Bonaventura, A.
Pignata, S.
ANNALS OF ONCOLOGY, 2024, 35 : S549 - S550
[10] Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use
Fung, Simon
Syed, Yahiya Y.
DRUGS & THERAPY PERSPECTIVES, 2024, 40 (02) : 53 - 60

← 1 2 3 4 5 →